solved Chapter 18 —along with several others in this textbook—has discussed

Chapter 18 —along with several others in this textbook—has discussed the shift from volume to value in healthcare and the importance of performance measurement to ensure accountability. How might the measurement burden affect our healthcare system, and what can be done to prevent or minimize this burden, particularly with regard to medication use?
Respond: The healthcare system in the United States has shifted from a volume based approach to more of an accountability approach, in recent years. Now, a fee for value service approach is being utilized, which provides incentives for health care providers to offer care at lower costs. Having the United States health care system transition to a value based approach, has caused the change in the way that providers charge for services and the amount of services that doctors can administer. This change has had some positive impacts on patients’ health and the quality of care that they are receiving. This new healthcare system can also help health care providers to manage larger populations of people, due to increased access to care, which can then lead to more out of network services. This measurement burden could affect our health care system negatively, by putting excessive strain on certain organizations resources or capabilities as well as understanding a patient’s needs and developing an appropriate payment model for them to follow. 
Respond: The shift to value from the volume, from quantity to quality health care has been one that has needed to happen for a long time. In saying that, all shifts have some burdens that they put on certain parts of the system. In this case, medication use may be abused or overused to try and ensure quality care. An example of this would be, in today’s healthcare, you can google your provider and leave them a review that is heavily weighted and displayed for all to see. In a situation of medication, someone could feel they were not given quality care by this particular provider because they were less inclined to prescribe certain medications for this patient’s ailments.
Fortunately, with the addition of risk-sharing agreements the burden of cost with be shared between healthcare payers and biopharmaceutical manufacturers. This allows more opportunity for patients to be able to receive and afford medications and holds biopharmaceutical manufacturers accountable for the effectiveness of their drugs. With basing these drug prices on their effectiveness and reimbursing healthcare payers if they are not the data collected is used in comparative effectiveness research to be able to offer patients and their providers the data that they need to show “real world” medical interventions. This will better equip them to make an informed decision about the care pathways they must choose from (Nash, 2019, p. 468).